| Project/Area Number |
18K16953
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 56060:Ophthalmology-related
|
|---|
| Research Institution | Kyorin University (2020-2022)
Nagoya University (2018-2019) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2023-03-31
|
| Project Status |
Completed (Fiscal Year 2022)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 加齢黄斑変性 / 脈絡膜新生血管 / OCT angiography / 血管の成熟化 / 抗血管内皮増殖因子薬 / OCT agniography / 網膜 / 光干渉断層血管撮影 |
|---|
| Outline of Final Research Achievements |
This study revealed that anti-vascular endothelial growth factor (VEGF) therapy led to a reduction in blood vessel density and vessel area in choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). However, despite consecutive anti-VEGF injections, CNV continued to expand. This CNV expansion did not correlate with the severity of exudative changes, highlighting a current limitation in AMD treatment. In other words, CNV may grow to a certain extent even with the current therapeutic approach.
Additionally, CNV expanded after half-dose photodynamic therapy (PDT), despite its effectiveness in managing exudation. These findings suggest that CNV expansion and exudation may be independent events and emphasize the need for new treatment strategies. Further research is necessary to develop improved therapeutic approaches that better address the challenges posed by CNV expansion and exudation in AMD.
|
| Academic Significance and Societal Importance of the Research Achievements |
AMDは日本人の失明原因の第4位であり、大変重要な疾患である。抗VEGF薬の登場により視力維持がある程度は可能となったとはいえ、薬剤の持続期間が短く、高額な薬剤の頻回な硝子体注射が必要である。視力の長期的な管理には未だ問題も多く、患者自身の負担増大のみならず医療経済的にもよりよいAMD治療の開発は重要な課題である。本研究ではAMDが完治しない理由の最大の原因と考えるCNVの拡大を最新画像検査にて明らかとし、現在の治療の限界点を提示した。今後は、この限界点を踏まえて新たな治療戦略を企てることが重要となるため、その足掛かりとなる本研究の意義は大きい。
|
